PAX7 and facioscapulohumeral muscular dystrophy: We recently performed a head-to-head comparison of published transcriptomic biomarkers alongside a novel biomarker based on PAX7 target gene repression in a meta-analysis across six independent data sets [five microarray-based and one limited RNA-Sequencing (RNA-Seq)] profiling FSHD and control skeletal muscle (28).